ARTICLE | Clinical News
Keryx's Auryxia meets in Phase III anemia study
March 30, 2016 1:31 AM UTC
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) rose $0.39 to $4.94 on Tuesday after its Auryxia ferric citrate met the primary endpoint in a Phase III trial to treat iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease (CKD).
In 3Q16, the company plans to submit an sNDA to FDA to add the indication to Auryxia's label. The therapy is an oral ferric iron-based phosphate binder. ...